Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. 1997

J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
Department of Biomedical and Therapeutic Sciences, University of Illinois College of Medicine, Peoria 61656-1649, USA. JFG@uic.edu

OBJECTIVE To develop a new pharmacokinetic model for ascorbic acid (vitamin C) since no previously published model describes ascorbic acid absorption and disposition over a broad physiologic range of doses and plasma concentrations. METHODS A new model was developed through exploratory simulations. The model was fitted to pharmacokinetic data obtained from seven healthy volunteers who underwent ascorbic acid depletion then gradual repletion. Concentrations of ascorbic acid were measured in plasma and urine. Final pharmacokinetic model parameter estimates were obtained using nonlinear regression analysis. RESULTS The new model included saturable absorption, distribution and renal tubular reabsorption parameters. The model described ascorbic acid concentrations in plasma, cells, and urine during depletion and gradual repletion phases with a residual error less than 15%. CONCLUSIONS The model was useful for obtaining a new understanding of the likely causes for the complex concentration-time profile observed during gradual repletion. At doses of 200 to 2500 mg per day, the plateau in pre-dose concentrations is largely due to apparent saturation of tissue uptake and less a function of oral bioavailability and renal excretion than previously thought.

UI MeSH Term Description Entries
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001205 Ascorbic Acid A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. Vitamin C,Ascorbic Acid, Monosodium Salt,Ferrous Ascorbate,Hybrin,L-Ascorbic Acid,Magnesium Ascorbate,Magnesium Ascorbicum,Magnesium di-L-Ascorbate,Magnorbin,Sodium Ascorbate,Acid, Ascorbic,Acid, L-Ascorbic,Ascorbate, Ferrous,Ascorbate, Magnesium,Ascorbate, Sodium,L Ascorbic Acid,Magnesium di L Ascorbate,di-L-Ascorbate, Magnesium
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
September 1952, The Journal of nutrition,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
June 1972, JAMA,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
November 2017, Pakistan journal of pharmaceutical sciences,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
October 2008, Pakistan journal of pharmaceutical sciences,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
April 2000, Antimicrobial agents and chemotherapy,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
January 2018, Drug design, development and therapy,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
April 2011, Biopharmaceutics & drug disposition,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
June 2000, Journal of psychopharmacology (Oxford, England),
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
February 2016, Malaria journal,
J F Graumlich, and T M Ludden, and C Conry-Cantilena, and L R Cantilena, and Y Wang, and M Levine
September 2006, Die Pharmazie,
Copied contents to your clipboard!